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Abstract
Osteoporosis or osteopenia occurs in about 44 million Americans, resulting in 1.5 million fragility
fractures per year. The consequences of these fractures include pain, disability, depression, loss of
independence, and increased mortality. The burden to the healthcare system, in terms of cost and
resources, is tremendous, with an estimated direct annual USA healthcare expenditure of about
$17 billion. With longer life expectancy and the aging of the baby-boomer generation, the number
of men and women with osteoporosis or low bone density is expected to rise to over 61 million
by 2020. Osteoporosis is a silent disease that causes no symptoms until a fracture occurs. Any
fragility fracture greatly increases the risk of future fractures. Most patients with osteoporosis are
not being diagnosed or treated. Even those with previous fractures, who are at extremely high risk
of future fractures, are often not being treated. It is preferable to diagnose osteoporosis by bone
density testing of high risk individuals before the first fracture occurs. If osteoporosis or low bone
density is identified, evaluation for contributing factors should be considered. Patients on long-term
glucocorticoid therapy are at especially high risk for developing osteoporosis, and may sustain
fractures at a lower bone density than those not taking glucocorticoids. All patients should be
counseled on the importance of regular weight-bearing exercise and adequate daily intake of
calcium and vitamin D. Exposure to medications that cause drowsiness or hypotension should be
minimized. Non-pharmacologic therapy to reduce the non-skeletal risk factors for fracture should
be considered. These include fall prevention through balance training and muscle strengthening,
removal of fall hazards at home, and wearing hip protectors if the risk of falling remains high.
Pharmacologic therapy can stabilize or increase bone density in most patients, and reduce fracture
risk by about 50%. By selecting high risk patients for bone density testing it is possible to diagnose
this disease before the first fracture occurs, and initiate appropriate treatment to reduce the risk
of future fractures.
Background
Osteoporosis is a silent disease that causes no symptoms
until a fracture occurs. It is a major public health concern,
with about 44 million American men and women, or 55%
of the population age 50 and over, having osteoporosis or
low bone density that can lead to fractures [1]. About 80%
of osteoporosis occurs in women and 20% in men. The
prevalence is increasing, with over 61 million expected to
have osteoporosis or low bone density by 2020. About
30% of Caucasian women age 50 and over have
Published: 14 July 2004
Clinical and Molecular Allergy 2004, 2:9 doi:10.1186/1476-7961-2-9
Received: 12 May 2004
Accepted: 14 July 2004
This article is available from: http://www.clinicalmolecularallergy.com/content/2/1/9
© 2004 Lewiecki; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media 
for any purpose, provided this notice is preserved along with the article's original URL. Clinical and Molecular Allergy 2004, 2:9 http://www.clinicalmolecularallergy.com/content/2/1/9
Page 2 of 11
(page number not for citation purposes)
osteoporosis, when defined as a T-score of less than -2.5 at
the spine, hip, or mid-forearm [2]. In men age 50 and
older, the prevalence of osteoporosis is about 19% [3].
There are about 1.5 million fragility fractures in the USA
each year, with 700,000 vertebral fractures, 300,000 hip
fractures, 250,000 wrist fractures, and 250,000 at other
skeletal sites. The lifetime risk of fracture is substantial.
Population data from Rochester, Minnesota, estimate that
at the age of 50, a Caucasian woman has about a 40% life-
time risk and a Caucasian man a 13% lifetime risk of frac-
ture of fracture at hip, spine, or distal forearm [4]. In
Malmö, Sweden, the lifetime risk of fracture of the hip,
spine, forearm or proximal humerus at age 50 was
reported to be 46% in women and 22% in men [5]. The
Dubbo study found that at the age 60 there was a residual
lifetime fracture risk of 56% for women and 29% for men,
assuming average life expectancy [6]. A woman's risk of
hip fracture is equal to her combined risk of breast, uter-
ine, and ovarian cancer [7]. Fractures of the spine and hip
are associated with an increased risk of chronic pain,
deformity, depression, disability, and death. About 50%
of those with a hip fracture will be permanently unable to
walk without assistance and 25% will require long-term
care [8]. The mortality rate five years after a fracture of the
hip or a clinical vertebral fracture is about 20% greater
than expected [9], with men having higher mortality rates
than women, even when standardized for age [10]. The
direct cost of osteoporotic fractures in the USA was about
$17 billion per year in 2001 [11], extrapolated from 1995
figures using the Medical Index of the Consumer Price
Index, with this value expected to rise greatly in future
years.
Bone density and bone strength
Osteoporosis is defined as "a skeletal disease character-
ized by compromised bone strength predisposing a per-
son to an increased risk of fracture. Bone strength
primarily reflects the integration of bone density and
quality." [12] Bone mineral density (BMD) correlates very
well with fracture risk, with the relative risk of fracture
approximately doubling (range 1.6–2.6) for every stand-
ard deviation decrease in BMD, depending on the skeletal
site measured and the type of fracture [13]. Many devices
and technologies are available for measuring BMD. Dual-
energy X-ray absorptiometry (DXA) is the method used to
diagnose osteoporosis according to criteria established by
the World Health Organization [14] [Table 1].
Non-BMD factors that may alter bone strength include
bone turnover, architecture (size and shape, or bone
geometry), microarchitecture, damage accumulation,
matrix properties, mineralization, and mineral properties.
These factors and probably many others that have not yet
been well-defined are collectively called "bone quality" or
"bone qualities." Accumulating knowledge regarding
bone qualities offers insight into the pathophysiology of
osteoporosis and metabolic bone disease, and helps in
understanding the mechanisms of action of bone-active
drugs. However, with the exception of bone turnover
markers and bone geometry, none of these are these pres-
ently have clinical applications.
The adult skeleton is in a constant state of remodeling, a
process whereby bone and bone matrix (mostly com-
posed of type 1 collagen) is continually being removed by
osteoclasts in discrete packets, or bone remodeling units,
followed by osteoblast-mediated bone formation and
mineralization. With high bone turnover states, such as
occurs with estrogen deficiency in the early postmenopau-
sal years, there are more bone remodeling units resulting
in a greater number of "stress-risers," or weakened areas of
bone. A stress-riser in bone is analogous to a scored line
on a sheet of glass, where the glass is more likely to break
than in an area that is not scored. Ultimately, thinning
and perforation of trabecular structures may occur, as well
as impaired mineralization. High bone turnover, which is
detected clinically by the finding of elevated markers of
bone resorption, has been shown to be an independent
risk factor for fracture [15].
Small bones, as in individuals with a small frame or in
women compared to men, are weaker than large bones.
This is consistent with the engineering concept that a
tubular structure, such as a long bone, has a greater ability
to resist bending forces as the diameter increases. Longer
hip axis length (the distance from the lateral surface of the
greater trochanter to the inner surface of the pelvis, along
the axis of the femoral neck), larger femoral neck-shaft
angle (the angle between the axis of the femoral neck and
the femoral shaft), and wider femoral neck diameter (the
width of the femoral neck at its narrowest portion) are
associated with increased risk of hip fracture [16]. This
may explain, in part, the lower risk of hip fracture in Chi-
nese and Japanese women compared to Caucasians,
despite similar BMD. A larger vertebral body is less likely
Table 1: Classification of Bone Mineral Density (World Health 
Organization) [14].
Classification T-score
Normal -1.0 or greater
Osteopenia Between -1.0 and -2.5
Osteoporosis -2.5 or less
Severe Osteoporosis -2.5 or less with a fragility fracture
The WHO classification is founded on epidemiological data in 
postmenopausal Caucasian women with BMD measured at the spine, 
hip, and forearm. The prevalence of osteoporosis in this group is 
approximately 30%, which roughly corresponds to the lifetime risk of 
fragility fracture.Clinical and Molecular Allergy 2004, 2:9 http://www.clinicalmolecularallergy.com/content/2/1/9
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to fracture than a smaller one, even with the same BMD,
since a larger cross-sectional area has greater resistance to
compressive forces [17].
Bone microarchitecture, best evaluated by bone biopsy,
concerns bone properties at the microscopic level, such as
the spatial distribution of trabecular rods and plates,
trabecular thickness and connectivity, cortical thickness
and cortical porosity. The horizontal trabeculae, which
stabilize the load-bearing vertical trabeculae, are subject
to thinning and perforation in patients with osteoporosis,
resulting in loss of bone strength and increased fracture
risk [18]. The number, size, and distribution of cortical
porosities may play a role in determining bone strength
[19].
Damage accumulation, such as the increasing number of
microfractures with advancing age, occurs at multiple
skeletal sites in some, but perhaps not all individuals [20].
While this has adverse effects on the biomechanical prop-
erties of bone, the relationship between microfractures
and clinical fractures is not clear, and the significance of
increased microdamage accumulation with antiresorptive
therapy is not known.
Bone matrix is the noncalcified portion of bone, 90% of
which is composed of type 1 collagen. It provides elastic-
ity and flexibility to bone. Inherited and acquired disor-
ders of the collagen fibrils, crosslinking, or non-
collagenous proteins may have serious consequences on
bone strength and fracture risk. Mild forms of metabolic
bone disease with abnormal collagen, such as osteogene-
sis imperfecta and Ehlers-Danlos syndrome, may some-
times masquerade as postmenopausal osteoporosis.
Mineralization is responsible for stiffness, or mechanical
rigidity, of bone. Too much (osteopetrosis) or too little
(osteomalacia) bone mineral can have adverse effects on
bone strength. Mineralization takes place in two phases:
the primary, or active bone formation phase, occurring
over a period of months, and the secondary, or slow
phase, which takes years. The second phase, which may be
responsible for as much as 50% of bone mineralization, is
incomplete in high bone turnover states. The rapid
increase in BMD over the first 6–12 months of bisphos-
phonate therapy is due to "filling of the remodeling
space" associated with the first phase of mineralization,
while the slower increase in BMD over the following years
is due to increased secondary mineralization allowed by
the reduced rate of bone turnover [21]. Even the size and
distribution of hydroxyapatite crystals may affect the
mechanical properties of bone, with animal studies sug-
gesting that a mix of small and large crystals are stronger
than only large crystals or only small crystals [22].
Clinical risk factors
Consideration of risk factors can provide helpful informa-
tion for patient management. It is enlightening to distin-
guish risk factors for osteoporosis from risk factors for
fracture, risk factors for hip fracture from risk factors for
vertebral fracture, and skeletal risk factors for fracture
from non-skeletal ones, since the clinical implications
will vary accordingly. For example, risk factors for oste-
oporosis, such as advanced age, small stature, or family
history, are commonly used in selecting patients for bone
density testing, and may determine whether the test is cov-
ered by insurance. Clinical risk factors for osteoporosis are
not a substitute for bone density testing, and in fact can-
not accurately predict which individual patients have low
bone density [23]. Risk factors for fracture, which overlap
risk factors for osteoporosis but are not totally the same,
can help determine which patients require medical inter-
vention. Skeletal risk factors for fracture, such as low bone
density or high bone turnover, may be treated with phar-
macologic agents. Non-skeletal risk factors for fracture,
such as poor balance and high risk for falling, require
other types of intervention, such as balance training and
hip protectors. Advancing age is a risk factor for oste-
oporosis and fractures for which there is no antidote.
Good nutrition, regular weight-bearing exercise, and
avoidance of cigarette smoking, alcohol excess and bone-
toxic drugs can maximize the genetic potential for skeletal
integrity. Validated risk factors for fracture also vary
according to the type of fracture, with many more risk fac-
tors identified for hip fracture than for vertebral fracture.
A list of common skeletal and nonskeletal risk factors for
hip fracture is in Table 2. The best validated risk factors for
vertebral fracture are low BMD, advancing age, and previ-
ous fracture.
Long-term glucocorticoid therapy
A meta-analysis of 66 BMD studies and 23 fracture studies
showed that oral glucocorticoid treatment with more than
prednisolone 5 mg per day or equivalent leads to a
decrease in BMD and increased risk of fracture [24]. The
increase in fracture risk begins within 3–6 months of start-
ing glucocorticoids, decreases soon after stopping, and is
Table 2: Selected Skeletal and Nonskeletal Risk Factors for Hip 
Fracture [15,48].
Skeletal Nonskeletal
Low BMD Advanced age
Previous fracture Mother with hip fracture
High bone turnover Anticonvulsant therapy
Small stature Frailty
Identification of skeletal and nonskeletal risk factors can help to 
customize therapy to address the issues of most importance in 
preventing fractures.Clinical and Molecular Allergy 2004, 2:9 http://www.clinicalmolecularallergy.com/content/2/1/9
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independent of age, sex, or underlying disease. Analysis of
the United Kingdom General Practice Research Database
(UK GPRD) of 244,235 patients on oral glucocorticoid
therapy showed that a low dose (less than 2.5 mg per day)
was associated with an increased risk of vertebral and non-
vertebral fractures, and doses greater than 2.5 mg per day
were associated with increased risk of vertebral, nonverte-
bral, and hip fractures [25]. Fracture risk was dose-
dependent, increasing dramatically as the dose increased.
The fracture risk associated with glucocorticoid therapy
appears to be related to average daily dose rather than
cumulative dose, suggesting that the adverse skeletal
effects are acute rather than chronic [26]. Some [27], but
not all [28], studies have shown that patients on glucocor-
ticoid therapy fracture at a higher BMD than patients not
on glucocorticoid therapy, suggesting problems with
bone quality that are independent of BMD, and that per-
haps treatment thresholds should be more aggressive for
glucocorticoid patients. A UK GPRD study of 170,818
patients on inhaled glucocorticoids showed increased risk
of vertebral, nonvertebral, and hip fractures compared to
controls, but suggested that the risk increase may have
been due to the underlying respiratory disease rather than
the inhaled glucocorticoids [29]. A meta-analysis of 27
studies showed that inhaled glucocorticoids (triamci-
nolone, budesonide, beclomethasone) in doses over 1.5
mg per day (0.75 mg per day for fluticasone propionate)
may be associated with a significant reduction in bone
density [30]. In a 2-year randomized placebo-controlled
trial of inhaled fluticasone in asthma patients, there was
no significant change in BMD with doses of 0.176 mg per
day [31]. There is no convincing evidence that intranasal
glucocorticoids in normally prescribed doses have any
clinically significant adverse effect on skeletal integrity
[32], although some studies have demonstrated suppres-
sion of the hypothalamic-pituitary-adrenal axis [33]. Fur-
ther study is needed to define the impact of intranasal
glucocorticoid formulation, dose, and combination with
oral or inhaled glucocorticoids on the development of
bone disease. The prevalence of glucocorticoid-induced
osteoporosis is often difficult to determine due to the con-
founding effects of comorbidities and polypharmacy. A
study of general practice patients in Iceland showed that
26% of those treated with oral glucocorticoids for more
than 3 months were diagnosed with osteoporosis, and
20% had a history of fragility fractures [34]. The patho-
physiology of glucocorticoid-induced osteoporosis is
multifactorial, and includes 1.) impairment of osteoblast,
osteocyte, and osteoclast function, leading to decreased
bone turnover and reduced microfracture repair; 2.) disor-
dered calcium metabolism, with reduced intestinal
absorption, increased renal excretion, and possible sec-
ondary hyperparathyroidism; and 3.) decreased synthesis
of sex hormones [35].
Diagnosis
Bone density testing
A clinical diagnosis of osteoporosis may be made in the
presence of a fragility fracture, provided other causes of
fracture have been ruled-out. A fragility fracture is any
fracture occurring after trivial trauma, such as falling from
the standing position, coughing, bending, or reaching.
Most fractures in adults, except those from major trauma,
such as auto accident or falling off a ladder, are fragility
fractures. The preferable method of diagnosing oste-
oporosis is by bone density testing, before the first fracture
has occurred. The WHO criteria may be used to classify
BMD, expressed as T-score, as normal, osteopenia, or
osteoporosis.
A T-score is the standard deviation (SD) variance of the
patient's BMD compared to a healthy young-adult refer-
ence population. It is calculated according to the follow-
ing formula, with BMD and SD expressed as g/cm2:
This formula shows that the T-score is dependent on fac-
tors other than the patient's BMD, and that a change in the
mean or SD of the reference population can result in a dif-
ferent T-score. For example, if the mean young-adult BMD
in the reference population is higher, the T-score will
decrease, and if the SD is lower, the T-score will increase.
This is a clinically import concept, since the reference pop-
ulation may vary according to the manufacturer of the
instrument, the software version installed, or the region of
interest being measured. For this reason, comparison of
serial DXA studies should always be done with absolute
BMD values in g/cm2, and not with T-scores.
A Z-score is the standard deviation (SD) variance of the
patient's BMD compared to an age- and sex-matched ref-
erence population, and should not be used to diagnose
osteoporosis. It is calculated according to the same for-
mula as the T-score, except that the reference population
is age- and ethnicity-matched instead of young-adult
matched.
The WHO classification system was originally devised as a
public health tool for evaluating the prevalence of oste-
oporosis in populations of postmenopausal women. It
was not intended for use in the diagnosis of osteoporosis
in individual patients. However, in the absence of a better
yardstick, it quickly came to be used in that fashion. The
T-score cut-off of -2.5 for diagnosing osteoporosis was
selected because it identified approximately 30% of post-
menopausal Caucasian women as having osteoporosis,
which is roughly the same as the lifetime risk of clinical
T-score
Patient’s BMD Mean Young-Adult BMD
 SD of Youn
= () − ()
1 g g-Adult BMD ()Clinical and Molecular Allergy 2004, 2:9 http://www.clinicalmolecularallergy.com/content/2/1/9
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fragility fractures in this population. The WHO criteria
apply to BMD measurement by DXA of the spine, hip and
forearm in postmenopausal women and in men age 65
and older [36]. At the present time, the WHO criteria
should not be used with BMD measurement devices other
than DXA, nor for measurement at skeletal sites other
than spine, hip, and forearm. Perhaps in the future, with
standardization of reference databases, and acquisition of
device-specific data on prevalence of osteoporosis and
fracture risk, the diagnosis of osteoporosis will be made
with devices other than DXA.
Who should be tested?
Bone density testing should be considered in anyone at
risk for osteoporosis, or being monitored for treatment of
osteoporosis, provided that the results of the test are likely
to play a role in patient management decisions. Of all the
published guidelines of indications for bone density test-
ing, the most comprehensive are those of the Interna-
tional Society for Clinical Densitometry (ISCD) [36],
listed in Table 3.
Evaluation of low bone density
It is prudent to have a high index of suspicion for contrib-
uting factors in every patient with low density. A T-score
of -2.5 or below is not always osteoporosis. It could be
metabolic bone disease, such as osteomalacia, or a local-
ized bone disorder, such as a bone cyst in the measured
skeletal site. A postmenopausal woman with osteoporosis
does not always have postmenopausal osteoporosis. She
could have malabsorption due to undiagnosed celiac dis-
ease, or possibly multiple myeloma. Table 4 lists diseases,
conditions, and medications commonly associated with
low bone density. In every patient with low BMD, it is rea-
sonable to consider measuring a complete blood count,
serum calcium, phosphorous, creatinine, alkaline phos-
phatase, liver enzymes, and thyroid stimulating hormone.
Tests that are often helpful include a 24-hour urine for cal-
cium, celiac antibodies, and in older patients, a serum and
urine protein electrophoresis. In selected patients, a serum
intact parathyroid hormone level, urinary free cortisol (or
other tests to rule out Cushing's syndrome), or additional
studies may be helpful.
Prevention and treatment
Nonpharmacologic therapy
Nonpharmacologic therapy can be divided into the cate-
gories of nutrition, lifestyle, and fall prevention. These
represent the foundation for the management of oste-
oporosis, without which patients are unlikely to achieve
the full benefit of pharmacologic therapy. Calcium and
vitamin D supplementation have been shown to increase
BMD [37] and reduce the risk of fractures [38] in prospec-
tive trials. The average American diet is deficient in cal-
cium, and many Americans have an insufficient daily
intake of vitamin D. The National Osteoporosis Founda-
tion recommends that all adults have a daily intake of at
least 1200 mg elemental calcium with diet plus supple-
ments, and 400–800 IU vitamin D per day for patients at
risk of deficiency [39].
Lifestyle intervention for osteoporosis includes regular
weight-bearing exercise and avoidance of unhealthy
behavior, such as cigarette smoking and excess alcohol
intake. Patients with low BMD and high risk for falling
may benefit from additional measures, such as muscle
strengthening, fall prevention, balance training, Tai Chi,
extra care with the dosing of certain drugs (e.g., sedatives,
hypnotics, antihypertensives, anticonvulsants), night-
lights, handrails, grab-bars, removal of slippery carpets
and dangerous obstacles at home, correction of impaired
eyesight and hearing, and the wearing of hip protectors.
The decision to treat
Since the goal of treatment is to prevent fractures, selec-
tion of patients for drug treatment should be based on
level of fracture risk. Current guidelines for initiation of
pharmacologic therapy [Table 5] are based on T-score or
T-score plus clinical risk factors. While these guidelines are
a helpful for appropriate patient populations, over-reli-
ance on T-scores alone may underestimate or overesti-
mate absolute fracture risk and lead to inappropriate
therapy. For example, a healthy 30 year-old premenopau-
sal woman with a T-score (or Z-score) of -2.1 probably has
a low 5–10 year absolute fracture risk and would probably
not benefit from pharmacologic therapy, while an elderly
man or woman with a T-score of -1.4 and a history of fra-
gility fracture is at high risk for future fracture and could
expect a significant reduction in fracture risk with therapy.
Efforts are currently underway to develop a standardized
Table 3: Indications for Bone Density Testing [36] (Official 
Position of the International Society for Clinical Densitometry).
1. All women aged 65 and older.
2. Postmenopausal women under age 65 with risk factors for 
osteoporosis.
3. Adults with a fragility fracture.
4. Adults with a disease or condition associated with low bone mass or 
bone loss.
5. Adults taking medication associated with low bone mass or bone 
loss.
6. Anyone being treated for low bone mass, to monitor treatment 
effect.
7. Anyone not receiving therapy, in whom evidence of bone loss 
would lead to treatment.
Women discontinuing estrogen should be considered for bone density 
testing/bone mass measurement according to the indications listed above. 
These indications provide a framework for selecting patients for bone 
density testing. In order to determine if the test is covered by 
insurance, it is important to be familiar with local requirements.Clinical and Molecular Allergy 2004, 2:9 http://www.clinicalmolecularallergy.com/content/2/1/9
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methodology for calculating and expressing absolute frac-
ture risk, which is arguably the best way of establishing
therapeutic thresholds. Personal issues and non-skeletal
effects of medications are also important to consider in
the decision to treat and drug selection [Table 6]
Pharmacologic therapy
The medications that are FDA-approved for the manage-
ment of osteoporosis may be divided into antiresorptive
agents (estrogen, alendronate, risedronate, and calci-
tonin) and anabolic agents, of which there is now only
one-teriparatide. These agents can be expected to stabilize
or increase BMD [Table 7] and reduce fracture risk by
approximately 50% in most patients. All of the FDA-
approved medications have been shown to reduce the risk
of vertebral fractures, while only estrogen, alendronate,
and risedronate have reduced the risk of hip fractures in
prospective clinical trials. [Table 8]
Table 4: Causes of Low Bone Mineral Density.
Inherited Nutritional Endocrine Drugs Other
Osteogenesis imperfecta Malabsorption Hypogonadism Glucocorticoids Multiple myeloma
Homocystinuria Chronic liver disease Hyperthyroidism Anticonvulsants Rheumatoid arthritis
Marfan's syndrome Alcoholism Hyperparathyroidism Long-term heparin Systemic mastocytosis
Hypophosphatasia Calcium deficient diet Cushing's syndrome Excess thyroid Immobilization
Vitamin D deficiency Eating disorder GnRH agonists
Low BMD may be the result of many medical disorders. There should be a high index of suspicion in all patients with low BMD for these types of 
contributing factors.
Table 5: Indications for Pharmacologic Therapy.
National Osteoporosis Foundation [39]
Initiate therapy to reduce fracture risk in women with:
1. BMD T-scores below -2.0 by central DXA with no risk factors
2. BMD T-scores below -1.5 by central DXA with one or more risk factors
3. A prior vertebral or hip fracture
American Association of Clinical Endocrinologists [47]
The following women may benefit from pharmacologic treatment of osteoporosis:
1. Women with postmenopausal osteoporosis (Women with low-trauma fractures and low BMD and women with BMD T-scores of -2.5 and 
below)
2. Women with borderline low BMD (e.g., T-scores of -1.5 and below) if risk factors are present
3. Women in whom nonpharmacologic preventive measures are ineffective (bone loss continues or low trauma fractures occur)
These recommendations are very similar, with the main difference being the T-score cut-off for treatment in patients with no other risk factors.
Table 6: Nonskeletal Effects of Pharmacologic Therapy.
Medication Pros Con
Estrogen Relieves Menopausal symptoms, Cholesterol, LDL, 
HDL
Uterine Bleeding, Thromboembolic Disorders, Stroke, 
Coronary Artery Disease, Estrogen Sensitive Tumors, 
Triglyceride, Breast Tenderness, Fluid Retention
Alendronate/Risedronate Weekly Dosing Complicated Administration, GI Effects
Raloxifene Cholesterol, LDL, Reduced Breast Cancer Risk?, 
Cardiovascular?
Hot Flashes, Thromboembolic Disorders, Leg Cramps
Nasal Calcitonin Ease of Administration, Analgesic Effect Nasal Irritation
Teriparatide Analgesic Effect? Osteosarcoma in Rats, Injectable, Refrigeration, 
Hypercalcemia
The selection of the best pharmacologic agent for an individual patient requires a thorough understanding of patient factors and all drug effects, 
both skeletal and nonskeletal.Clinical and Molecular Allergy 2004, 2:9 http://www.clinicalmolecularallergy.com/content/2/1/9
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The Women's Health Initiative was the first large prospec-
tive randomized placebo-controlled trial to show reduc-
tion of hip fracture, vertebral fracture, and other
nonvertebral fractures with conjugated equine estrogen
(CEE) plus medroxyprogesterone acetate (MPA) [40] and
CEE alone [41]. However, the study was stopped before its
planned completion date due to increased risk of adverse
events. Considering the small but significant increase in
Table 7: Bone Density Response to Therapy.
Generic Name Brand Name Spine Hip
Estrogen Various
Alendronate Fosamax
Risedronate Actonel
Ibandronate Boniva
Calcitonin Miacalcin --
Raloxifene Evista
Teriparatide Forteo
This table illustrates direction of change in bone mineral density (BMD) with each type of drug. This does not represent a comparison of the magnitude of BMD 
change with different drugs. All of the medications that are currently approved by the FDA, with the exception of salmon calcitonin, have been shown 
to increase BMD at both the spine and hip.
Table 8: Fracture Risk Reduction in Response to Therapy.
Generic Name Brand Name Spine Fracture Non-Vertebral 
Fracture
Hip Fracture
Estrogen Various
Alendronate Fosamax
Risedronate Actonel
Ibandronate Boniva
Calcitonin Miacalcin
Raloxifene Evista
Teriparatide Forteo
This table illustrates the direction of change in fracture risk with each type of drug. This does not represent a comparison of the magnitude of fracture risk 
reduction with different drugs. While all FDA-approved medications have been shown to reduce the risk of spine fracture, only estrogen, alendronate, 
and risedronate have reduced the risk of hip fracture in randomized placebo-controlled trials. 
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the risk of breast cancer, stroke, coronary heart disease,
and venous thromboembolic disease with CEE plus MPA,
and the increase risk of stroke with CEE alone, it is likely
that estrogen will not be used as a drug of first choice for
the treatment of osteoporosis, and that its main use will
be for the control of menopausal symptoms. The bisphos-
phonates, alendronate and risedronate, are both proven
to reduce the risk of hip fractures, and may be good
choices in elderly patients and any patients with high risk
of hip fracture. Raloxifene and calcitonin are useful agents
where reduction of hip fracture risk is not a primary con-
cern, with the added benefit that raloxifene may reduce
the risk of breast cancer and calcitonin may have an anal-
gesic effect in patients with acute painful vertebral frac-
tures. Teriparatide, human recombinant 1–34 parathyroid
hormone, is approved for use in women and men at high
risk for fracture. Despite its greater expense and the incon-
venience of daily subcutaneous injections for a 2-year
course of therapy, this agent is a welcome addition to the
pharmacologic armamentarium for selected patients.
Current evidence suggests that there is no added benefit to
combining teriparatide with alendronate, but giving a
bisphosphonate following a course of treatment with ter-
iparatide may serve to preserve the bone mass previously
gained. Combination therapy in general is discouraged,
since there are no studies showing that it offers additional
benefit in terms of fracture risk reduction.
Glucocorticoid-induced osteoporosis (GIO)
Long-term term glucocorticoid therapy may have devas-
tating consequences in terms of loss of bone density and
increased fracture risk. Any patient being started on oral
glucocorticoid therapy with the intent to treat for more
than 3 months should be considered for bone density test-
ing and bone-protective medication. Table 9 shows the
guidelines of the American College of Rheumatology for
the prevention and treatment of GIO [42].
Monitoring treatment
The ultimate indicator of efficacy for osteoporosis therapy
is reduction of fracture risk. In clinical trials, this is done
by comparing fractures rates in a group receiving active
medication compared to placebo. For individual patients
in clinical practice, BMD is normally used as a surrogate
measurement of changes in bone strength and fracture
risk in response to therapy. An increase or stabilization of
BMD is associated with reduction in fracture risk [43],
although other measures of bone qualities, particularly
changes in bone turnover markers [44], are correlated to
changes in fracture risk as well. Patients started on phar-
macologic therapy are typically retested in 1–2 years in
order to be sure there has been no loss of BMD, and
retested at longer intervals once response to therapy has
been shown. Patients at very high risk for bone loss, such
as those on glucocorticoid therapy, may need to be tested
as often as every 6 months, until stability of bone mass
has been demonstrated.
Discontinuation of treatment
It is intuitive that pharmacologic therapy should be con-
tinued as long as fracture risk is high, and stopped when
that is no longer the case. Prolonged therapy adds to
patient cost and inconvenience, and possibly increases the
risk of drug toxicity due to longer exposure. Clinical trials
and knowledge of drug mechanisms of action are helpful
in predicting the likely outcome of discontinuation, and
suggestive of appropriate measures for follow-up. Discon-
tinuing estrogen, raloxifene, or calcitonin therapy is likely
to be associated with rapid loss of therapeutic effect and
subsequent bone loss due to sex hormone deficiency and/
Table 9: Management of Glucocorticoid-Induced Osteoporosis [42].
Patient beginning therapy with glucocorticoid (prednisone equivalent of ≥5 mg/day with plans for treatment duration of ≥3 months):
1. Modify lifestyle risk factors for osteoporosis (Smoking cessation or avoidance. Reduction of alcohol consumption if excessive.)
2. Instruct in weight-bearing physical exercise.
3. Initiate calcium supplementation.
4. Initiate supplementation with vitamin D (plain or activated form).
5. Prescribe bisphosphonate (use with caution in premenopausal women).
Patient receiving long-term glucocorticoid therapy (prednisone equivalent of ≥5 mg/day):
1. Modify lifestyle risk factors for osteoporosis. (Smoking cessation or avoidance. Reduction of alcohol consumption if excessive.)
2. Instruct in weight-bearing physical exercise.
3. Initiate calcium supplementation.
4. Initiate supplementation with vitamin D (plain or activated form).
5. Prescribe treatment to replace gonadal sex hormones if deficient or otherwise clinically indicated.
6. Measure bone mineral density (BMD) at the lumbar spine and/or hip.
If BMD is not normal (i.e., T-score < -1.0), then prescribe bisphosphonate (use with caution in premenopausal women). Consider calcitonin 
as second-line agent if patient has contraindication or intolerance to bisphosphonate therapy.
If BMD is normal, follow-up and repeat BMD measurement annually or biannually.
The devastating effects of glucocorticoids on bone can be largely mitigated by early intervention with bone-protective agents.Clinical and Molecular Allergy 2004, 2:9 http://www.clinicalmolecularallergy.com/content/2/1/9
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or aging. Therefore, patients at high risk for fracture who
stop these drugs should probably soon be started on
another anti-fracture drug. Bisphosphonates, having a
strong affinity for bone and a long bone half-life, have
been shown to have persistence of suppression of bone
turnover for months to years after cessation of therapy.
This suggests that patients who have been taking an oral
bisphosphonates for years may continue to benefit from
drug effects for a long time after discontinuation, with the
duration of persistent effect varying according to the phar-
macological properties of the bisphosphonate used. With
teriparatide, there is evidence that discontinuation may be
quickly followed by bone loss, which can be prevented by
initiating bisphosphonate therapy.
Nonresponders
In clinical trials, the overwhelming majority of patients
treated for osteoporosis with antiresorptive or anabolic
medication stabilize or increase BMD and benefit from a
reduction in fracture risk. In clinical practice, approxi-
mately 10% of elderly patients treated with a bisphospho-
nate have been shown to lose BMD [45], defined as a
BMD decrease more than the Least Significant Change
(LSC) at a 95% level of confidence, a value that can be cal-
culated for each bone densitometry center. Medical evalu-
ation of these BMD losers revealed a previously
unrecognized contributing factor, or secondary cause of
osteoporosis in about 50%. Although there is no universal
consensus on the definition of non-response to therapy,
defining nonresponse in terms of BMD loss more than the
LSC is a useful tool in clinical practice, and is cause for fur-
ther medical investigation. Common causes for
nonresponse include poor adherence (not taking medica-
tion or not taking it correctly), calcium or vitamin D defi-
ciency, and comorbidities (diseases, conditions or
medication that impair drug effect or are associated with
osteoporosis) [46].
When to refer to an osteoporosis specialist
The care of osteoporosis patients crosses all medical spe-
cialty lines. Primary care specialists and most medical sub-
specialists may justifiably claim the right to manage
osteoporosis in their patients, and do it well. In a small
percentage of patients with unusual clinical presentations,
intolerance to standard medications, or poor response to
therapy, additional expertise may be required. Table 10
shows established guidelines for referral to an osteoporo-
sis specialist [47].
Summary
Osteoporosis is a common disorder of low bone strength
due to a combination of factors that include low BMD,
high bone turnover, altered microarchitecture, geometry,
damage accumulation, and mineralization, leading to
increased risk of fractures. The consequences of fragility
fractures are serious-disability, loss of independence,
chronic pain, and increased mortality. Patients on long-
term oral glucocorticoid therapy, even at low doses, are at
increased risk for fracture. Inhaled glucocorticoids in
sufficiently high doses may increase fracture risk. Intrana-
sal glucocorticoids, in doses normally prescribed, do not
appear to have clinically significant adverse skeletal
effects. BMD testing is the most important clinical tool for
diagnosing high risk patients before the first fracture
occurs, allowing for timely and appropriate medical
intervention to strengthen bones and reduce the risk of
fracture.
Table 10: When to Refer to an Osteoporosis Specialist [47].
Referral to an osteoporosis specialist is appropriate when the patient is in any of the following circumstances:
1. Has osteoporosis that is unexpectedly severe or has unusual features at the time of initial assessment
Has very low BMD (a T-score below -3.0 or a Z-score below -2.0)
Has osteoporosis despite young age (premenopausal)
Has fractures despite borderline or normal BMD
2. Has a suspected or known condition that may underlie the osteoporosis (for example, hyperthyroidism, hyperparathyroidism, hypercalciuria, 
Cushing's syndrome, or hypogonadism)
3. Is a candidate for combination therapy
4. Is intolerant of approved therapies
5. Fails to respond to treatment
Takes estrogen yet has low baseline BMD
Is undergoing treatment yet shows an apparent loss of BMD on serial studies
Has fractures on treatment
Most osteoporosis patients can be successfully managed by the primary care physician, but a small percentage with unusual or difficult problems can 
benefit from consultation with an osteoporosis specialist. Referral to an osteoporosis specialist is appropriate when the patient is in any of the 
following circumstances:Clinical and Molecular Allergy 2004, 2:9 http://www.clinicalmolecularallergy.com/content/2/1/9
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